



[Call Toll-free 1-800 856-7842](tel:18008567842) or [828-254-0881](tel:8282540881) with Extension listed

Name of Study: **DILIN's Prospective Study-(UNCCH)**

LINK: <https://clinicaltrials.gov/ct2/show/NCT00345930?term=dilin&rank=1>

PI: Dr. Paul Hayashi, MD (Patients seen at Asheville Gastroenterology Site- Dr. William R. Harlan)

Research Coordinator: Roberta Golden x [3570](tel:8283503627) or Direct-828-350-3627

Summary: Suspected drug-induced liver injury within past 6 months

Enrollment Ends: Approximately 2020

Inclusion:

- Evidence of liver injury known or suspected to be related to consumption of a drug within last 6 months.
- Serum ALT or AST > 5 x ULN or alk phos > 2 x ULN confirmed on 2 consecutive blood draws in subjects with previous normal values.
- If BL ALT, AST or Alk Phos are known to be elevated, then ALT or AST >5 x BL or Alk Phos >2 x BL on 2 consecutive blood draws. BL will be defined as the avg of at least 2 prior measurements within the previous year.

Exclusion:

- Competing cause of liver injury.
- Known, preexisting autoimmune hepatitis, primary biliary cirrhosis, PSC, or other chronic biliary tract disease.

Acetaminophen hepatotoxicity